126 related articles for article (PubMed ID: 26825003)
1. Expression of p53 and HER2/Neu in Kenyan Women With Primary Ovarian Carcinoma.
Mutuiri AP; Nzioka A; Busarla SV; Sayed S; Moloo Z
Int J Gynecol Pathol; 2016 Nov; 35(6):537-543. PubMed ID: 26825003
[TBL] [Abstract][Full Text] [Related]
2. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
[TBL] [Abstract][Full Text] [Related]
3. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
4. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung.
Saad RS; Liu Y; Han H; Landreneau RJ; Silverman JF
Mod Pathol; 2004 Oct; 17(10):1235-42. PubMed ID: 15167937
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
8. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study.
Verri E; Guglielmini P; Puntoni M; Perdelli L; Papadia A; Lorenzi P; Rubagotti A; Ragni N; Boccardo F
Oncology; 2005; 68(2-3):154-61. PubMed ID: 16020953
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
10. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
11. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
[TBL] [Abstract][Full Text] [Related]
12. Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1).
Badr KM; Nolen JD; Derose PB; Cohen C
Hum Pathol; 2004 Feb; 35(2):184-9. PubMed ID: 14991535
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma.
García-Velasco A; Mendiola C; Sánchez-Muñoz A; Ballestín C; Colomer R; Cortés-Funes H
Clin Transl Oncol; 2008 Jun; 10(6):367-71. PubMed ID: 18558584
[TBL] [Abstract][Full Text] [Related]
14. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
15. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
[TBL] [Abstract][Full Text] [Related]
17. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.
Nijman HW; Kenemans P; Poort-Keesom RJ; Verstraeten RA; Mensdorff-Pouilly S; Verheijen RH; Melief CJ; Hilgers J; Meijer CJ
Eur J Obstet Gynecol Reprod Biol; 1999 Apr; 83(2):201-6. PubMed ID: 10391533
[TBL] [Abstract][Full Text] [Related]
18. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
[TBL] [Abstract][Full Text] [Related]
20. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
